The association between different antihypertensive drugs and erectile dysfunction (ED) was examined in a cohort of type II diabetes patients identified in the UK General Practice Research Database (GPRD). The GPRD contains details of diagnoses, prescribing, investigations, risk factors, outcomes, and hospital referrals, together with basic demographic information for approximately six million patients from more than 450 representative general practices throughout the UK. A total of 634 cases and 2526 controls were included for analysis. Unconditional logistic regression analysis was performed to assess the risk of ED after adjusting for age at diabetes diagnosis date, cigarette smoking, depression, glycemic control, use of HMG-CoA reductase inhibitors, use of histamine receptor antagonists, use of digitalis medicines, and use of nitrates. Increased risk of ED was observed among patients taking the following antihypertensives: ACE inhibitors (OR ¼ 1.47, 95% CI ¼ 1.21, 1.80) and alpha blockers (OR ¼ 1.54, 95% CI ¼ 1.11, 2.12). However, we identified a nearly 30% reduction in risk among patients on diuretics (OR ¼ 0.73, 95% CI ¼ 0.54, 0.99). No statistically significant increase in risk was observed among users of beta blockers and calcium channel blockers (OR ¼ 1.05, 95% CI ¼ 0.85, 1.31) and (OR ¼ 1.14, 95% CI ¼ 0.91, 1.43), respectively. The results of this study confirm the strong and recognized effect of comorbidities in a diabetic population, but also require additional experimental and observational studies to further understand the potential benefit of diuretics and other ED treatments such as PDE5 inhibitors.
Introduction
Almost every antihypertensive class of medications has been associated with erectile dysfunction (ED). Some of the most studied antihypertensives have included reserpine, beta blockers, diuretics, and clonidine. Yet few studies have looked at the antihypertensive therapy-ED association in a type II diabetes population.
In the Treatment of Mild Hypertension Study (TOMHS), the incidence of ED was lowest in the patients taking an alpha blocker (doxazosin) and highest in those on chlorthalidone (a diuretic). 1 The disappearance of ED during treatment was greatest in the doxazosin group (87.5% for doxazosin and 55.0% for all other drugs combined). Alpha blockers are believed to have the potential to interfere with corporal smooth muscle constriction. Rare problems with emission and ejaculation have also been reported. 2 Thiazide diuretics were also linked with ED in a multicenter, randomized, double-blind study of 625 hypertensive men. 3 Compared with propanolol monotherapy, the addition of hydrochlorothiazide significantly impaired libido, gaining or maintaining tumescence, and ejaculation (Po0.05).
Sexual dysfunction is a known complication of therapy with beta blockers. [4] [5] [6] [7] [8] In TOMHS, the cardioselective beta blocker acebutolol did not result in a significant increase in ED compared with placebo.
1 However, decreased b 1 -receptor selectivity occurs with increasing dosages and may elicit ED. Propanolol is the most common beta blocker associated with ED due to its high lipophilicity and nonselective beta blockade.
As a class, calcium channel blockers are associated with a low incidence of ED. 9 In a study evaluating patients who received slow-release nifedipine 40-80 mg/day for 52 weeks, diastolic blood pressure was reduced to below 90 mmHg in 80%. 10 Nifedipine produced the least worsening of libido but resulted in deterioration in ejaculation and tumescence compared with atenolol and captopril.
As ACE inhibitors have no effect on the sympathetic nervous system, the incidence of sexual dysfunction should be minimal. 11 Indeed, tertiary data report the rates of ED for all currently available ACE inhibitors to be less than 1%. 12 This study is based on the hypothesis that patients who receive antihypertensive treatment will have moderate to no increase in ED risk. It is expected that individuals on ACE inhibitors or diuretics will have a reduced risk of ED.
Materials and methods
A case-control study nested in a cohort of type II diabetes patients was conducted to examine the relationship between antihypertensive treatment and ED among patients observed in the UK General Practice Research Database (GPRD). The diabetic cohort was followed from June 1, 1987 to October 23, 2001 .
Cases
A total of 634 ED cases were identified based on diagnosis codes in the GPRD. Patients with a diagnosis or history of cancer, history of heart disease, unknown cigarette smoking status, and/or spinal cord injury were excluded from the study.
Controls
Controls were randomly selected from the non-ED diabetic cohort after restricting to the age range of cases. A patient was eligible to be a control if he/she had no diagnosis or history of cancer, no history of heart disease, and no spinal cord injury. As with cases, only controls with known cigarette smoking status were included for analyses. Approximately four times the number of cases were selected, and thus 2526 controls were included for analyses.
The ED diagnosis date served as the index date for cases. Patients who ever used ACE inhibitors, alpha blockers, beta blockers, calcium channel blockers, and diuretics were identified. Potential confounding variables included age at diabetes diagnosis; duration of diabetes (defined as ED diagnosis dateFtype II diabetes diagnosis date for casesFand the last date of follow-upFtype II diabetes diagnosis date for controls); use of HMG-CoA reductase inhibitors (statins); use of histamine receptor antagonists; use of digitalis medicines; use of nitrates; depression (as indicated by a prescription of benzodiazepines, tricyclics, or selective serotonin reuptake inhibitors); use of antidiabetic drugs (as indicated by insulin or sulfonylurea use); and cigarette smoking.
Analysis
All risk analyses were performed utilizing unconditional logistic regression models with SAS s statistical software (SAS Institute, Cary, NC, USA).
Results
As seen in Table 1 , the mean length of follow-up for cases and controls was 8.0 and 6.6 y, respectively. The mean age of cases was 54.5 y compared to a mean age of 58.8 y among controls. Mean duration of type II diabetes was similar in both groups, 3.1 y for cases and 3.2 y for controls. In general, more cases were on antihypertensives compared to controls. However, there was an exception to this as 16% of controls were on diuretics compared to 12% of cases.
The goal of the analysis was to determine whether a significant difference in ED risk exists between patients on different antihypertensive treatments. All five logistic regression models adjusted for age at type II diabetes diagnosis, duration of type II diabetes, statins, histamine receptor antagonists, digitalis medicines, nitrates, depression, glycemic control, and smoking. Table 2 shows that patients on ACE inhibitors were 47% more likely to have ED 
Discussion
The fact that the cases were type II diabetics does not limit the validity of these results. While surveys may be the best way to measure ED prevalence, we were confident that we could identify a large number of ED cases in a database through a diabetic cohort. Indeed, the prevalence of ED is 95% in diabetic men more than 70 y of age, and increases with duration and complications of diabetes. 13 The use of the GPRD provided a quick way of studying the effect of antihypertensives on erectile function in a population at high risk for ED.
To our knowledge, the present study may be the only case-control study to look at ED risk among type II diabetes patients receiving antihypertensive treatment. This study provides new information in the field of hypertension therapy and its effect on ED incidence. It was specifically designed to look at the major antihypertensive classes, and extensive information was collected on potential confounders in this at-risk population. With the exception of diuretics, the data demonstrate moderate or no increase in risk among most antihypertensives, and this is consistent with previous studies. 1, 2, [4] [5] [6] [7] [8] [9] 11, 12 The fact that a protective effect was observed among diuretic users was quite unexpected and surprising, despite the use and acceptance of diuretics as a firstline treatment for hypertension.
14 Two factors influenced the decision to study ED in a diabetic cohort. First, given that ED is an under-reported condition, our thought was that more cases could be identified in this population. Second, some insight may be gained into the complexity and interrelationship between the components of insulin resistance syndrome and risk of ED.
Lower incidence rates of ED attributable to ACE inhibitors may be because the renin-angiotensinaldosterone system is not a direct constituent of the sympathetic nervous system. When enalapril 5-10 mg/day was administered to 62 men, at 24 and 48 months of treatment, no relationship was found between the drug and ED. 1 In our study, however, a 47% higher risk of ED was observed among ACE inhibitor users (OR ¼ 1.47, 95% CI ¼ 1.21, 1.80). It is possible that men with symptoms of ED are more likely to be prescribed ACE inhibitors because they have a lower risk of causing ED. As a result, the observed association of these particular drugs with ED may be confounded by the presence of comorbidities.
The blocking of a 1 -receptors results in blood vessel dilation. Alpha blockers have the potential to interfere with corporal smooth muscle constriction. Consequently, increased blood inflow may occur in the corporal artery, which could result in tumescence. Therefore, alpha blockers have a relatively low incidence of ED. In fact, in a study of 934 men, the incidence of ED with prazosin use was 0.6%. 15 As was the case with ACE inhibitors, any potential protective effect with alpha blockers was not observed (OR ¼ 1.54, 95% CI ¼ 1.11, 2.12). Once again, the results demonstrate how the strong effect of comorbidities likely overwhelms any possible reduction in risk.
Diuretics are typically prescribed as initial therapy for hypertension. Thiazide diuretics have been associated with ED, decreased libido, and failed ejaculation. 11, [16] [17] [18] However, the validity of these findings has been questioned. 19 One study concluded that ED and failed ejaculation were associated more with age than with diuretic use. 17 However, a thiazide diuretic studied in Great Britain was associated with ED in 36% of patients. 20 Nevertheless, thiazides lack central nervous system, autonomic nervous system, and hormonal effects, which supports the hypothesis that they play a small role in ED. The results of this study tend to support the hypothesis and reveal a protective role for diuretics (OR ¼ 0.73, 95% CI ¼ 0.54, 0.99).
It is hypothesized that beta blockers decrease b 2 vasodilatation of the corpora cavernosum. 4, 5 Subsequent peripheral vasoconstriction may lead to a decrease in genital blood flow, resulting in ED. We observed essentially no change in risk among beta blocker users (OR ¼ 1.05, 95% CI ¼ 0.85, 1.31). It was not determined whether patients switched beta blockers though. Switching from a nonselective to a selective beta blocker (atenolol, bisoprolol, metoprolol, acebutolol, and betaxolol) may alleviate ED. Calcium channel blockers decrease intracellular calcium entry, thereby decreasing systemic vascular resistance and blood pressure. Intracellular calcium provides an important link between the neuroendocrine components of sexual function and the mechanical and secretory processes that are necessary for sexual response. Despite this, there have been no significant reports of sexual dysfunction associated with the use of calcium channel blockers. In fact, no increase in risk was noted in our study (OR ¼ 1.14, 95% CI ¼ 0.91, 1.43).
Possible caveats to the study include the fact that it was not determined whether diuretics served as the first line of treatment for this patient population. It is conceivable that patients on diuretics had a better health status with fewer comorbidities. Similarly, duration of antihypertensive therapy was not evaluated. However, patients with hypertension typically require long-term daily therapy and are likely to be compliant. As the study used prescriptions of various antidepressants rather than actual depression diagnostic codes, all depressed patients may not have been captured.
The accuracy of diagnosis data in the GPRD has been studied previously and was found to be acceptable for research purposes. 21, 22 The results of this study warrant further investigation into the potentially protective effect of diuretics against ED, particularly among Type II diabetes patients who have been advised against taking PDE5 inhibitors for the treatment of ED. It is unlikely, however, that a change in antihypertensive treatment to diuretics alone will be sufficient. Diabetic men tend to have more severe comorbidities (eg vascular disease and neuropathies), and treatment with diuretics is usually reserved for patients initially diagnosed with hypertension. In general, diabetic men with ED tend to be less responsive to treatment possibly due to the multiple causes of diabetes-associated ED.
On the other hand, a recent study by Goldstein et al 23 demonstrated that vardenafil, a PDE5 inhibitor, improved erectile function in diabetic men whether they had poor glycemic control or not. Thus, it would be of interest to observe the degree of ED risk reduction among diabetic patients who take diuretics in addition to PDE5 inhibitors.
